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Abstract 24 
The first studies of histamine and diabetes date back to the 1950s. Since that time the involvement 25 
of histamine in diabetes was related to its well known vasoactive properties and permeability 26 
leakage effects. In particular, the first evidence for a correlation between histamine and diabetes 27 
arose in 1989 when an increase in plasma and leucocyte histamine content was observed. Limited 28 
independent evidence followed in the subsequent two decades, focusing on both histamine 29 
glyceamic control and macro- and microvascular complications of diabetes. However, recent 30 
observations have sparked the question whether it is time to reconsider the functional contribution 31 
of histamine in diabetes. We reveal an interesting upsurge in the field which provides scope for new 32 
insights into the role of histamine in diabetes.  33 
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Abbreviations: 37 
ADP= action potential duration; AGEs = advanced glycation end-products; BM = basement 38 
membrane; BRB = blood-retinal barrier; CGRP = calcitonin gene related peptide; CKD =  chronic 39 
kidney disease; DAO = diamine oxidase; DiO = diet-induced obesity; ESRD = end-stage renal 40 
disease; H1-4Rs = histamine H1-4Rs; HbA1 = glycated hemoglobin; 
HDC = histidine decarboxylase; 41 
STZ = streptozotocin;  TGF- β = tissue growth factor-β; TCAs = tricyclic antidepressants; Vmax = 42 
maximum rate of depolarization; VEGF = vascular endothelial growth factor; ZO-1 =  zonula 43 
occludent-144 
 3 
 45 
1 Introduction 46 
Diabetes mellitus can be considered a family of chronic degenerative disorders associated with a 47 
hyperglycemic status caused by either the loss of insulin production due to the destruction of beta 48 
pancreatic cells, decreased insulin sensitivity, or both [1, 2]. In 2014, the global prevalence of 8.3% 49 
has been estimated and by the end of 2030 this value is expected to rise up to 55% [3], resulting in 50 
obvious devastating consequences for healthcare expenditure worldwide. All the antidiabetic drugs 51 
currently available, although effective in reducing the risk of acute complications, such as 52 
hypoglycemia and hyperglycemia [4], are not effective in reversing the progression of this chronic 53 
and degenerative disorder. Indeed, diabetic patients are still at a high risk to develop longstanding 54 
complications including cardiovascular disease, such as coronary artery disease, and microvascular 55 
diseases, including neuropathy, retinopathy and nephropathy. Therefore, a better understanding of 56 
the underlying pathophysiology should contribute to new effective therapeutic approaches. Among 57 
the different mediators proposed to contribute to the pathophysiology of diabetes, histamine 58 
involvement has always been controversial and considered almost marginal. However, several lines 59 
of evidence support the contribution of histamine to the diabetic milieu resulting from the persistent 60 
hyperglycemia. For instance, the advanced glycation end-products (AGEs) have been demonstrated 61 
to activate mast cells whose degranulation may contribute to a vicious cycle, ultimately resulting in 62 
a low-grade inflammation typical of chronic diseases such as diabetes [5]. Therefore, this review 63 
aims to revisit the concept of histamine in the pathophysiology of diabetes and, in particular, its 64 
complications.  65 
2 Histamine and glycaemia 66 
Histamine is involved in a wide variety of pathophysiological events mostly related to the 67 
inflammatory response through four receptors, namely H1-4Rs.  The first studies of histamine and 68 
diabetes date back to the 1950s. Since that time the involvement of histamine in diabetes was 69 
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related to its well-known vasoactive properties and permeability leakage effects correlated to 70 
microvascular complications. In particular, the first evidence for a correlation between histamine 71 
and diabetes came in 1989 through the work of Gill and colleagues when they reported an increase 72 
in plasma and leucocyte histamine content which was claimed to contribute to the underlying 73 
pathogenesis evoking endothelial permeability [6]. These findings were in keeping with in vivo 74 
studies of experimental diabetes suggestive of an increased histaminergic tone in diabetic rodents. 75 
Indeed, histamine was found to be increased in plasma, kidney, brain, lung, heart, pancreas and 76 
intestine [6, 7] of diabetic rats. Independent evidence also suggested a parallel imbalance of the 77 
anabolism and catabolism of this amine with an increased synthesis and a simultaneous decreased 78 
catabolism [8-11]. For instance, a significant drop in intestinal diamine oxidase (DAO) activity [7] 79 
as well as an increase of histidine decarboxylase (HDC) activity in various tissues [12] were 80 
observed, thus providing evidence for a nascent histamine pool. The very recent observation of a 81 
reduced prevalence of hyperglycemia in HDC
-/-
 NOD mice (an animal model of spontaneous type 1 82 
diabetes) in comparison with the wild-type counterpart [13] strongly lends weight to this original 83 
hypothesis. 84 
More intriguingly, it has been reported that histamine plasma and aortic synthesis [10] in diabetic 85 
rats are reduced when insulin is administrated [14], thus strongly supporting the hypothesis for an 86 
interconnection between histamine and glycaemic status. This hypothesis is further strengthened by 87 
the study of Azevedo and colleagues (1990) reporting an increase of pancreatic islet histamine 88 
content in streptozotocin (STZ)-induced diabetes rats [15]. Interestingly, recent data suggest the 89 
involvement of the peripheral H3R in the insulin-histamine loop (Supplementary Figure 1). Indeed, 90 
Nakamura and colleagues (2014) provided the first evidence for a potential diabetogenic effect of 91 
the pancreatic H3R, through reporting the presence of functional histamine H3R in this tissue. In 92 
particular, it has been demonstrated that H3R activation in pancreatic beta cells by imetit (PubChem 93 
CID 3692) inhibits the insulin secretion associated with high glucose levels in MIN6 cells [16]. 94 
Moreover, the same authors reported H3R expression in pancreatic alpha cells, indicating that H3R 95 
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activation may reduce glucagon production by αTC1.6 cells in a non-hyperglycemic condition [17]. 96 
Notably, although the H3R has been known to play a critical role in homeostatic regulatory 97 
functions, such as control of food intake and maintenance of body weight [18], its contribution to 98 
diabetes is controversial [18-24] and still far from being fully understood. Indeed, the H3R inverse 99 
agonist clobenoprit (PubChem CID 2790) has been demonstrated to increase the hypothalamic 100 
histamine release and reduce the energy intake in normal and leptin-resistant mice with diet-induced 101 
obesity (DiO) [25]. So far, some newly synthesized H
3
R antagonists have been specifically tested 102 
in diabetic animal models demonstrating an effectiveness in reducing non-fasting glucose levels by 103 
potentially blocking the increase of HbA1 [26]. More interestingly, the strategy of an H3R 104 
antagonism combined with a phenylsulfonylurea (well-known insulinotropic drugs) moiety has 105 
been explored [27]; although an effective prototype remains elusive. On the contrary, the activation 106 
of H3Rs in mice has been reported to decrease food intake and increase energy expenditure. Chronic 107 
dosing with a H3R agonist reduces body weight, fat mass, hyperleptinemia, and hyperinsulinemia in 108 
DiO mice [28].  Conversely, the protean H3R agonist proxyfan (PubChem CID 6421522) in mice 109 
improves glucose excursion increasing plasma insulin levels without affecting plasma glucagon 110 
levels [29]. Furthermore, the mildly obese H3R-deficient mice also demonstrate leptin and insulin 111 
resistance with impaired glucose tolerance [28]. Notably, the majority of these data were obtained 112 
before the clear demonstration of H3R peripheral expression [16, 30-34]. In particular, the 113 
pancreatic localization of the H3R raises the question of contradictory effects mediated by 114 
peripheral and central H3R.   115 
Conflicting data concerning the involvement of H2R on glycaemia has also arisen. Its antagonism 116 
was reported to decrease [35], not affect [36, 37] and increase [38, 39] glucose levels. In 117 
comparison, the clinical experience with antipsychotic drugs generated clearer evidence for the 118 
involvement of the central H1R in the development of a diabetic phenotype [40]. Consistently, it has 119 
been found that the intra-ventricle or –hypothalamic administration of an H1R agonist induces 120 
satiety evoking an anti-obesity effect [41, 42]. Moreover, a strategy based on the contemporary H1R 121 
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agonism and H3R antagonism was demonstrated to have the potential to reduce obesity also in 122 
patients with comorbidities such as diabetes [43]. 123 
3 Histamine and diabetes complications 124 
As mentioned above, despite the effectiveness of the different anti-diabetic strategies in controlling 125 
glycaemic levels, due to the glucose variability, patients are still exposed to a high risk of 126 
developing one or more of the longstanding and serious complications [4]. According to the 127 
definitions by the World Health Organization, the complications can be divided into macrovascular 128 
complications (including coronary artery disease, peripheral arterial disease and stroke) and 129 
microvascular complications (including diabetic nephropathy, neuropathy and retinopathy). 130 
Notably, for each new case of one given complication, a higher probability to display another one 131 
has been clearly documented [44].  132 
Interestingly, a higher content of histamine in the anatomical districts involved in the diabetic 133 
longterm complications has been reported in different studies [6, 7]. Independently from the source 134 
of histamine within these districts, due to an activation of mast cells, a recruitment of basophils, an 135 
imbalance in the amine anabolism/catabolism or all three, the increased histaminergic tone is a 136 
common feature of the different complications and deserves to be further clarified. In particular, 137 
based on its vascular actions, histamine has been suggested to be a key triggering stimulus for the 138 
functional microangiopathy in diabetes mellitus, from retinopathy to nephropathy. However, its 139 
complete functional contribution to diabetes microvascular complications is yet to be elucidated. 140 
3.1 Histamine and macrovascular complications 141 
Cardiovascular diseases (CVD) are one of the leading cause of death in diabetics, with an increased 142 
rate of heart disease or stroke from two- to four-fold compared to non-diabetic patients [45]. 143 
Notably, histamine has been reported to regulate several cardiovascular and endothelial functions 144 
through concerted actions on both smooth muscle and endothelial cells. These actions result in 145 
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vasoconstriction or vasodilation based on histamine level, diameter and initial vessel tone, and 146 
relative location within the coronary circulation [46]. Again the first evidence for histamine 147 
involvement in diabetic macrovascular complications comes from the 1980s studies, when the 148 
histamine metabolism in both aortic endothelial and subjacent smooth muscle cells of control and 149 
diabetic rats was studied [47]. Despite such intriguing initial results, the hypothesis suggested was 150 
not further developed, with sparse, indirect and almost contrasting data remaining in the literature.  151 
The evidence for a role of histamine stems from mast cell activation during the coronary blood 152 
vessel inflammation underling the atherogenesis process [48, 49], but also from its release from 153 
activated platelets [50]. Indeed, the number of mast cells was found to be increased in the narrow 154 
parts of blood vessels or at the site of plaque rupture in patients suffering from ischemic heart 155 
diseases [51, 52]. Notably, histamine release was demonstrated to significantly increase in coronary 156 
circulation during myocardial ischemia irrespective of the incidence of risk factors such as 157 
hypertension, type 2 diabetes, or dyslipidaemias [53].  158 
Among the different receptors, historically the macrovascular effects of histamine seems to be 159 
mostly related to the H1R and H2R, but no specific studies were designed to investigate the whole 160 
histamine receptor family and only one observation claims the ability of H3R to regulate the 161 
coronary vascular response [54]. H1R has been reported to mediate the overexpression of the 162 
adhesion molecules [55] and the activation of nitric oxide synthase [55-57] evoked by histamine in 163 
vascular endothelial cells. H2R has been demonstrated to cause coronary dilation in both an 164 
endothelium independent [56] and dependent [54] manner. 165 
Apart from atherosclerosis, patients with diabetes mellitus also exhibit QT (QTc) interval 166 
prolongation and increased QTc dispersion. Interestingly, HDC
-/-
 mice with aging showed a 167 
decrease in maximum rate of depolarization (Vmax) and action potential duration (ADP)90 168 
prolongation comparable to those observed in the wild-type counterpart following diabetes 169 
induction by STZ administration [58]. This observation is still far from being conclusive, but it is in 170 
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keeping with the suggested arrhythmogenic potential of histamine [59, 60].  Although no specific 171 
receptor involvement have been described, histamine has been reported to induce Purkinje-fibers 172 
depolarization drive to ventricular tachycardia [61]. In mastocytosis patients, when a massive mast 173 
cells recruitment and degranulation occur, cardiac arrest has been observed [62]. Moreover, atrial 174 
fibrillation was described consequently to anaphylaxis reaction to venom and pollen 175 
immunotherapy in patients with established hyperhistaminemia [63]. Finally, a recent study 176 
pointing at a connection between histamine and diabetes macrovascular complications concluded 177 
that manipulation of cardiac mast cell function with nedocromil (PubChem CID 50294), a mast cell 178 
stabilizer, is sufficient to attenuate cardiomyopathy stimulated by diabetes [64].   179 
Collectively, in the literature, there are not enough data to support any conclusive dissertation on 180 
the role of histamine in the development/maintenance of the macrovascular complication of 181 
diabetes, with the majority of its effects ascribable to its general anti-inflammatory properties.  182 
3.2 Histamine and microvascular complications 183 
The vasoactive properties of histamine led to the hypothesis advocating its contribution to the 184 
development and maintenance of diabetes-related microvascular complications. As discussed 185 
above, the role of the amine was investigated in the different end-organ(s). 186 
3.2.1 Diabetic neuropathy 187 
Diabetic neuropathy is an heterogeneous family of nerve disorders resulting in improper locomotor 188 
and visceral organ dysfunctions at the level of peripheral, central, and visceral sensorimotor and 189 
motor nerves [65]. According to this definition we can recognize peripheral, autonomic, proximal, 190 
or focal neuropathy. Among these different neuropathies the peripheral subtype is the most 191 
common. As a consequence of the peripheral nerve degeneration, triggered by persistent 192 
hyperglycaemia, and according to the affected nerves, diabetes patients suffer from pain, weakness, 193 
and eventual loss of sensation in addition to severe chronic pain syndromes. 194 
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The wheal response to intradermal application of histamine in diabetic patients have been assessed 195 
since 1930 [66], but its involvement in pain transmission was clearly recognized only by Schwartz 196 
and collaborators in 1991. So far many strands of evidence have pointed to histaminergic 197 
neurotransmission as an important factor in the control of pain [67-70]. Indeed, diabetic patients 198 
have been described to be less responsive to histamine as well as other neurogenic inflammation 199 
mediators such as substance P. In addition, a bidirectional relationship between different 200 
neurotransmitters and histamine exists [71]. The mRNA of H1R has been detected in many 201 
substance P positive neurons [72] and histamine has been shown to mediate the release of substance 202 
P and glutamate [73]. Also, the expression of H1R and/or H3R within calcitonin gene related peptide 203 
(CGRP) positive neurons [72] was determined. CGRP and histamine can establish a vicious circle 204 
inducing one another [70, 74, 75]. 205 
Although histamine has been reported to modulate nociception through all four types of its receptor, 206 
H1R [69, 76-78], H2R [76, 78, 79], H3R [78, 79] and H4R [80-85], in 2014 the H3R antagonists were 207 
reported as very promising for neuropathic pain [86]. However, only one study was designed to 208 
evaluate the antinociceptive effect of the H3R in a diabetic model. This respective study showed 209 
that the selective agonist immepip (PubChem CID 3035842) reversed formalin-induced 210 
hyperalgesia in both phases of the formalin test [87]. This effect could be associated with both H3R 211 
peripheral activation, resulting in a reduction in inflammatory peptides release, and H3R central 212 
activation, leading to the inhibition of pain transmission [88-92]. Consistent with this theory, 213 
immepip (PubChem CID 3035842) was found to inhibit mechanical, not thermal sensitivity in rats, 214 
but was shown to affect neither mechanical nor thermal sensitivity in mice [93]. Moreover, the role 215 
of H3R receptor in nociception is still controversial, with different antagonists, including 216 
GSK189254 (PubChem CID 9798547), GSK334429 (PubChem CID 11452311) and ABT-239 217 
(PubChem CID 9818903), demonstrated to be effective in reducing the sensitivity to mechanical 218 
stimuli [94] or in relief from surgically- and virally-induced neuropathic pain as well as 219 
inflammatory pain [82, 95, 96], respectively. The discrepancy emerging from the above described 220 
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literature can be specifically explained by the observation that the H3R receptor is expressed both as 221 
an autoreceptor and heteroreceptor which inhibits the release of histamine [97] and other 222 
neurotransmitters, respectively, including acetylcholine, noradrenaline, dopamine and serotonin 223 
[98-102]. 224 
Notably, histamine has also been shown to play a role in autonomic neuropathy. Indeed, the 225 
deranged autonomic function of the airways in diabetic patients with autonomic neuropathy has 226 
been demonstrated to elicit an exaggerated response to histamine-induced bronchoconstriction 227 
[103]. A direct stimulation of bronchial smooth muscle contraction combined with vagal-mediated 228 
reflexes after stimulation of rapidly adapting irritant receptors and C-fibers has been argued to be 229 
the mechanism underling the histamine-induce bronchoconstriction, while bronchomotor tone is 230 
mainly controlled by the parasympathetic nervous system. Therefore, the exaggerated response to 231 
histamine in diabetic patients could be due to the widespread autonomic damage to the respiratory 232 
parasympathetic and sympathetic pathways (including non-adrenergic non-cholinergic pathways 233 
influencing airway tone) and/or denervation hypersensitivity [104-111]. However, despite the above 234 
observations the role of histamine in autonomic neuropathy is still far from clear.   235 
3.2.2 Diabetic retinopathy 236 
Diabetic retinopathy is still one of the major worldwide cause of blindness. Its development can be 237 
divided into non-proliferative, with microaneurysms, hard exudates, haemorrhages, and venous 238 
abnormalities and proliferative, with neovascularization, pre-retinal or vitreous haemorrhages, and 239 
fibrovascular proliferation [112, 113]. Development of glaucoma, retinal detachment, and vision 240 
loss may also happen at this stage [114].  241 
A possible role for histamine in this context was postulated when diabetic retinopathy was mainly 242 
considered a microvascular complication of endothelial dysfunction with capillary basement 243 
membrane (BM) thickening, pericyte and endothelial cell loss, blood-retinal barrier (BRB) 244 
breakdown and leakage, acellular capillaries, and neovascularization [115, 116]. Indeed, most of 245 
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these vascular effects are consistent with the vasoactive properties of histamine. Antihistamines, 246 
such as diphenhydramine (PubChem CID 3100), astemizole (PubChem CID 2247) and ranitidine 247 
(PubChem CID 3001055), have been shown to reduce the leakage of retinal vessels in diabetic rats 248 
and humans [117, 118], but also to attenuate blood-brain barrier permeability and to ameliorate 249 
cerebral blood flow disturbances [119]. 250 
In particular, it was reported that histamine specifically affects the zonula occludent (ZO)-1 251 
expression in cultured retinal microvascular endothelial cells [120]. Interestingly, the same authors 252 
described a similar inhibitory effect on ZO-1 expression for both high glucose (20mM) and low 253 
insulin (10
-12
M) culturing condition [121]. These data provide a mechanistic interpretation of the 254 
ability of histamine to induce a BRB dysfunction in both experimental diabetes and diabetic 255 
patients [118, 122, 123], suggesting that the increased histaminergic tone consequent to the diabetic 256 
milieu could directly account for the BRB breakdown and leakage vascular, for many years 257 
considered pivotal in the pathogenesis of diabetic retinopathy. These effects can be considered at 258 
least qualitatively equivalent to those observed for the vascular endothelial growth factor (VEGF) 259 
on permeability leakage [124]. 260 
The possible involvement of histamine in diabetic retinopathy is still plausible, although not deeply 261 
investigated, when, according to the neurodegenerative nature of this disease, the other components 262 
of the retina, such as neurons and glial cells are taken into account. It is currently acknowledged 263 
that cellular, molecular, and functional changes are evidenced in all the retina cellular 264 
compartments [115, 116, 125-127] at an early stage of diabetic retinopathy. Intriguingly, an 265 
increase in histamine synthesis was observed within the retinas of diabetic rats [117, 128]. This was 266 
due to an over-expression of the HDC enzyme in both the retinal neurons and glia [129]. As 267 
mentioned above for plasma, aorta and pancreas, an insulin-histamine loop does exist also within 268 
the retina. The histamine overproduction induced by diabetes was decreased by both the HDC 269 
inhibitor or insulin administration in experimental diabetes [128]. 270 
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Therefore, collectively the data in the literature suggest that histamine could at least participate in 271 
the neural cell contribution to the diabetes-induced vascular leakage. 272 
3.2.3 Diabetic nephropathy 273 
Diabetic nephropathy is one of the most important causes of chronic kidney disease (CKD), and 274 
therefore of end-stage renal disease (ESRD) in Western nations.  It has been estimated that the risk 275 
of developing CKD is increased by a factor of 12-fold in type 1 diabetes and 6-fold in type 2 276 
diabetes, compared with non-diabetic individuals [130]. About one-third of diabetic patients begin 277 
to show persistently high urinary albumin excretion, thence being at high risk to develop in primis 278 
diabetic ESRD, but also cardiovascular diseases and premature mortality, even without progression 279 
to ESRD [131]. 280 
Intriguingly, the first evidence for a possible role of histamine in the development of diabetic 281 
nephropathy arose from studies performed in STZ diabetic rats in which histamine levels, consistent 282 
with the generalized increase of the amine induced by diabetes, were found to be significantly 283 
increased in the kidney [132, 133]. Again, a greater tissue HDC activity without a concomitant 284 
decrease in histaminase activity could account for this event [133] especially at the glomerular level 285 
which has been identify as the major site of intrarenal histamine synthesis and accumulation [109, 286 
134]. The demonstrated ability of histamine to increase salt and water excretion [135-137], decrease 287 
the ultrafiltration coefficient by reducing the total filtration surface area [137], and increase renin 288 
release [138] led to the hypothesis of a direct involvement of histamine in regulating the renal 289 
microcirculation. For a long period, histamine was claimed to affect the glomerular 290 
microcirculation. However, recent evidence suggest and support the hypothesis of direct effects of 291 
histamine on glomerular integrity and function, far beyond simply modifying the glomerular 292 
hemodynamic microcirculation [139].  293 
At the tubular level, the first evidence of a histamine detrimental effect on tubular integrity and 294 
function was already available in the 1960s and 1970s when several reports suggested that mast 295 
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cells may be involved in kidney diseases, but as mast cells were not easily detected by routine 296 
histochemical staining, they were ignored or forgotten by nephrologists for many years [140]. In the 297 
normal kidney, mast cells are constitutively present at a low number. However, their density 298 
increases in the renal cortical tubulointeirstizium, in the periglomerular and perivascular area, but 299 
not in glomeruli, in a variety of human renal diseases including diabetic nephropathy [140-142]. 300 
Moreover, mast cells have occasionally been found in the wall of atrophied tubules [142]. In 301 
particular, it has been shown that with disease progression, the number and degranulation status of 302 
mast cells increased, suggesting that histamine released by mast cells into the tubular interstitium 303 
may promote renal inflammation and fibrosis [141, 142]. Indeed, histamine has been reported to 304 
promote fibrosis affecting the tissue growth factor (TGF)-β/Smad3/4 axis in the lung [143].  305 
In the past several decades, all the renal effects of histamine were ascribed only to H
1
R and H
2
R, 306 
both identified in the glomeruli [12, 132]. Consistent with results obtained in rats [138], it was 307 
found in humans that the H
2
R is the subtype present in glomeruli and involved in the cAMP 308 
accumulation subsequent to the increasing histamine [144]. Moreover, it has been demonstrated that 309 
histamine modulates mesangial cells and glomeruli via H
1
R [145]. In the last few years, convergent 310 
lines of evidence strongly support the conclusion that all four histamine receptors are present and 311 
functional in the human nephron, although with a differential anatomical topology [34]. Notably, 312 
among them, both the H3R and the H4R have been reported to be profoundly upregulated at the 313 
tubular level in STZ treated rats, which also displayed parallel renal damage (mostly again at the 314 
tubular level) [33, 146]. These latter data led to a new interest in histamine in kidney 315 
(patho)physiology supporting the hypothesis that it could directly and specifically contribute to the 316 
onset/progression of diabetic nephropathy. 317 
4 Conclusion 318 
Is it really the time to reconsider the functional contribution of histamine in diabetes? Indeed, 319 
although still far from conclusive, different elements point to a clear role of histamine in diabetes 320 
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and diabetic complications etiopathogenesis. The evidence is strong in some cases, sometimes 321 
independent, but sometimes contradictory; despite this heterogeniety, when viewing the timeline of 322 
interest for histamine involvement in this disease (Figure 1) it appears phasic with a clear upturn 323 
and renewal in interest in the last couple of years, thanks to the very recent discovery of a direct 324 
effect of histamine on glycaemia [13, 16, 17] as well as a profound up-regulation of both H3R and 325 
H4R in the  diabetic animal kidney  [33, 146]. As a whole, the revisit of the literature herein clearly 326 
shows growing independent lines of evidence for a bidirectional connection between histamine and 327 
diabetes (Table I).  328 
Table I. The diabetes-histamine loop: the state of the art  
Diabetes complication Diabetes affects 
histamine 
Histamine influences 
the progression 
Receptor involved 
   H1R H2R H3R H4R 
macrovascular  HDC and 
histamine in 
aortic endothelial 
and smooth 
muscle cells 
atherogenesis 
coronary dilation, 
arithomogenic activity 
(QT-prolongation) 
++ ++ + n.d. 
microvascular       
neuropathy       
peripheral 
neuropathy 
 pain control,  
neurogenic 
inflammation 
n.d. n.d. + n.d. 
autonomic 
neuropathy 
  bronchoconstriction n.d. n.d. n.d. n.d. 
retinopathy  HDC and 
histamine 
 vascular leackage ++    
nephropathy  HDC, 
histamine, H3R 
and H4R 
expression 
 salt and water 
excretion,  
ultrafiltration 
coefficient,  
 renin release 
+ + ? ? 
++ = strongest evidence; + = spare evidence; ? = under 
investigation/charactherization; n.d. = no data 
  
329 
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 330 
Therefore, a pathophysiological role for this amine cannot be discounted anymore and new studies 331 
specifically aimed to assess its function in the onset and progression of the longstanding diabetes 332 
complications are strictly warranted. The state of the art on histamine in diabetes is recapitulated in 333 
Figure 1.  334 
 335 
Figure 1. Milestones in the story of histamine and diabetes. Timeline of major events in the 336 
history of histamine and its link to diabetes and its complications - 1930s to present day. The phasic 337 
interest with the recent upsurge in the last couple of years is depicted. 338 
 339 
As reported in Table I, not all the diabetic complications have been provided with the same level of 340 
compelling evidence. Many blind spots remain regarding the role of histamine in macrovascular 341 
complications where the effect of the amine seems to be mostly related to its general vasoactive 342 
properties rather than to a specific function in diabetes. The discrepancies often observed in the 343 
literature can be mostly ascribed to the different models adopted as well as to the doses, the 344 
administration route and the actual selectivity of the compound used, which could differentially 345 
affect the central and peripheral histaminergic system. More notably, the majority of the evidence 346 
for histamine involvement in the different diabetes complications arises from studies not directly 347 
aimed to assess its role in diabetic disease. This is in particular the case for diabetic peripheral 348 
neuropathy where the studies were designed to assess a general role in nociception and/or 349 
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neuropathic pain. Other fields, such as retinopathy, have found using new strategies, effective and 350 
specific pharmacological tools that have downgraded the antihistaminergic approach to a supporting 351 
role. However, since many of the investigations were prior to the discovery of the newest histamine 352 
receptor members H3R and H4R, [147] there is scope for new insights in histamine and diabetes, 353 
and the opportunity to develop new antihistamine drugs to overcome the paucity of effective 354 
therapies.  355 
 356 
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